Gene-Editing Treatment Cuts Swelling Attacks by 87% in Trial

Imagine getting one treatment that could stop a potentially deadly condition for good.

Intellia Therapeutics just announced their gene-editing treatment succeeded in a pivotal trial for hereditary angioedema, a rare condition causing life-threatening swelling attacks. This marks the first time a treatment that edits genes directly inside the body has worked in a major Phase 3 trial.

The treatment uses CRISPR, the Nobel Prize-winning technology that acts like molecular scissors to edit DNA. Through a single infusion lasting a few hours, it turns off the gene causing overproduction of a peptide that triggers the swelling attacks.

The results speak for themselves. Patients saw their attacks reduced by 87% compared to placebo. Six months after the one-time treatment, 62% of patients experienced zero attacks and didn't need any other medications.

The company reported favorable safety results, with the most common side effects being infusion reactions, headaches, and fatigue. This was a critical benchmark after concerns arose from a separate trial where a patient died from liver toxicity with a different Intellia treatment.

The Ripple Effect

This breakthrough goes far beyond one condition. What makes this trial historic is that it's the first successful test of editing genes directly inside the body, opening doors for treating countless genetic diseases.

The only other FDA-approved CRISPR treatment requires removing cells, editing them in a lab, then putting them back into patients. This new approach is simpler and could work for diseases where that method isn't possible.

CEO John Leonard highlighted how far the field has come. "When you think about where we started with CRISPR, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible," he said. Now that possibility is becoming reality.

Intellia has already started submitting their application to the FDA and plans to complete it later this year. If approved, the treatment called lonvoguran ziclumeran could launch in early 2027.

The permanence of the treatment sets it apart. In nearly six years of trials, not a single patient has seen the effects fade over time. While Leonard hesitates to call it a cure, the evidence suggests people could be free from this disease after just one treatment.

The breakthrough proves that permanently changing genes to stop disease isn't science fiction anymore.